The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic.
This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.VirusesWikipedia:WikiProject VirusesTemplate:WikiProject Virusesvirus articles
This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 articles
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.
Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about the detrimental effects of remdesivir on kidney function which might consequently lead to Acute Kidney Injury (AKI).13 Apr. 2023
https://www.ncbi.nlm.nih.gov › pmc
Acute kidney injury in COVID-19 patients receiving remdesivir - NCBI 102.130.28.14 (talk) 08:38, 2 October 2023 (UTC)[reply]
Not done No source linked. Bon courage (talk) 08:46, 2 October 2023 (UTC)[reply]
I was surprised reading this article that there was very little mention of any of the past criticism of this drug. It sounds like it has had a lot of supporters and detractors since 2020, yet there is very little mention of any of the previous criticism (a couple sentences from what I read). The WHO recently walked back their criticism of the drug WHO recommends against the use of remdesivir in COVID-19 patients
So my question is:
if the general scientific consensus has agreed that Remdesivir does work, does that mean there is little need of much discussion on any previous detractions or concerns about its quick approval?
I would be of the opinion that the FDA not convening outside panels for this drug is notable, but I would like to know what this articles frequent editors think. (more sources: forbes and science.org) 134.134.139.84 (talk) 18:57, 11 October 2023 (UTC)[reply]
Any good sources giving an overview? So far as I can see the modern view is that remdesevir is a bit rubbish for COVID.[1]Bon courage (talk) 19:14, 11 October 2023 (UTC)[reply]
Semi-protected edit request on 28 January 2024
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.
Possible side effects include death. 73.121.109.117 (talk) 11:52, 28 January 2024 (UTC)[reply]
.svg){kind=small}
.svg){kind=small}
Not done No source linked. Bon courage (talk) 08:46, 2 October 2023 (UTC)